Vactosertib is also a novel TβR1 inhibitor, currently under development in clinical trials, that inhibits the phosphorylation of Smad2 and Smad3 proteins, thereby suppressing EMT in tumor cells, and has been shown to be safe and well tolerated in phase I clinical studies [80,81,82]. The gene discussed is TBR1; the disease is neoplasm.